Swiss National Bank Sells 35,100 Shares of IQVIA Holdings Inc. $IQV

Swiss National Bank cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 498,680 shares of the medical research company’s stock after selling 35,100 shares during the quarter. Swiss National Bank owned approximately 0.29% of IQVIA worth $94,719,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the period. Empowered Funds LLC raised its holdings in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in IQVIA during the second quarter valued at approximately $514,000. Wedbush Securities Inc. lifted its holdings in IQVIA by 10.7% during the second quarter. Wedbush Securities Inc. now owns 1,608 shares of the medical research company’s stock worth $253,000 after buying an additional 156 shares during the period. Finally, Penserra Capital Management LLC increased its holdings in shares of IQVIA by 10.3% in the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after acquiring an additional 90 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a report on Thursday, February 5th. Jefferies Financial Group lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, IQVIA currently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Stock Performance

NYSE IQV opened at $171.21 on Wednesday. The firm’s 50 day simple moving average is $205.12 and its 200 day simple moving average is $207.39. The firm has a market capitalization of $29.05 billion, a price-to-earnings ratio of 21.78, a P/E/G ratio of 1.72 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.